Teamed up with Lyell, Juno/WuXi joint venture files IPO betting on China's CAR-T future
JW Therapeutics got its start on the back of CAR-T tech from Juno Therapeutics, a joint venture banking on the promise of marrying cutting-edge American technology with WuXi AppTec’s state-of-the-art process development and late-stage clinical infrastructure in China. Four years later, a collaboration with a Juno co-founder’s new startup is cementing a bridge to the public market.
Lyell has granted JW exclusive China rights to two CAR-T programs targeting AFP and GPC3, antigens applicable broadly across solid tumors, the companies announced last week. JW noted in its IPO filing on the Hong Kong stock exchange that it’s also nabbed rights to the T-cell anti-exhaustion functionality.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.